37 results on '"Fokkens, W J"'
Search Results
2. Association between outdoor air pollution and chronic rhinosinusitis patient reported outcomes
- Author
-
Peeters, S., Wang, C., Bijnens, E. M., Bullens, D. M. A., Fokkens, W. J., Bachert, C., Hellings, P. W., Nawrot, T. S., and Seys, S. F.
- Published
- 2022
- Full Text
- View/download PDF
3. Erratum to: Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA
- Author
-
Bousquet, Jean, Bewick, M., Cano, A., Eklund, P., Fico, G., Goswami, N., Guldemond, N. A., Henderson, D., Hinkema, M. J., Liotta, G., Mair, A., Molloy, W., Monaco, A., Monsonis-Paya, I., Nizinska, A., Papadopoulos, H., Pavlickova, A., Pecorelli, S., Prados-Torres, A., Roller-Wirnsberger, R. E., Somekh, D., Vera-Muñoz, C., Visser, F., Farrell, J., Malva, J., Andersen Ranberg, K., Camuzat, T., Carriazo, A. M., Crooks, G., Gutter, Z., Iaccarino, G., de Keenoy, E. Manuel, Moda, G., Rodriguez-Mañas, L., Vontetsianos, T., Abreu, C., Alonso, J., Alonso-Bouzon, C., Ankri, J., Arredondo, M. T., Avolio, F., Bedbrook, A., Białoszewski, A. Z., Blain, H., Bourret, R., Cabrera-Umpierrez, M. F., Catala, A., O’Caoimh, R., Cesari, M., Chavannes, N. H., Correia-Da-Sousa, J., Dedeu, T., Ferrando, M., Ferri, M., Fokkens, W. J., Garcia-Lizana, F., Guérin, O., Hellings, P. W., Haahtela, T., Illario, M., Inzerilli, M. C., Lodrup Carlsen, K. C., Kardas, P., Keil, T., Maggio, M., Mendez-Zorrilla, A., Menditto, E., Mercier, J., Michel, J. P., Murray, R., Nogues, M., O’Byrne-Maguire, I., Pappa, D., Parent, A. S., Pastorino, M., Robalo-Cordeiro, C., Samolinski, B., Siciliano, P., Teixeira, A. M., Tsartara, S. I., Valiulis, A., Vandenplas, O., Vasankari, T., Vellas, B., Vollenbroek-Hutten, M., Wickman, M., Yorgancioglu, A., Zuberbier, T., Barbagallo, M., Canonica, G. W., Klimek, L., Maggi, S., Aberer, W., Akdis, C., Adcock, I. M., Agache, I., Albera, C., Alonso-Trujillo, F., Angel Guarcia, M., Annesi-Maesano, I., Apostolo, J., Arshad, S. H., Attalin, V., Avignon, A., Bachert, C., Baroni, I., Bel, E., Benson, M., Bescos, C., Blasi, F., Barbara, C., Bergmann, K. C., Bernard, P. L., Bonini, S., Bousquet, P. J., Branchini, B., Brightling, C. E., Bruguière, V., Bunu, C., Bush, A., Caimmi, D. P., Calderon, M. A., Canovas, G., Cardona, V., Carlsen, K. H., Cesario, A., Chkhartishvili, E., Chiron, R., Chivato, T., Chung, K. F., D’Angelantonio, M., de Carlo, G., Cholley, D., Chorin, F., Combe, B., Compas, B., Costa, D. J., Costa, E., Coste, O., Coupet, A. -L., Crepaldi, G., Custovic, A., Dahl, R., Dahlen, S. E., Demoly, P., Devillier, P., Didier, A., Dinh-Xuan, A. T., Djukanovic, R., Dokic, D., du Toit, G., Dubakiene, R., Dupeyron, A., Emuzyte, R., Fiocchi, A., Wagner, A., Fletcher, M., Fonseca, J., Fougère, B., Gamkrelidze, A., Garces, G., Garcia-Aymeric, J., Garcia-Zapirain, B., Gemicioğlu, B., Gouder, C., Hellquist-Dahl, B., Hermosilla-Gimeno, I., Héve, D., Holland, C., Humbert, M., Hyland, M., Johnston, S. L., Just, J., Jutel, M., Kaidashev, I. P., Kaitov, M., Kalayci, O., Kalyoncu, A. F., Keijser, W., Kerstjens, H., Knezović, J., Kowalski, M., Koppelman, G. H., Kotska, T., Kovac, M., Kull, I., Kuna, P., Kvedariene, V., Lepore, V., Macnee, W., Maggio, M., Magnan, A., Majer, I., Manning, P., Marcucci, M., Marti, T., Masoli, M., Melen, E., Miculinic, N., Mihaltan, F., Milenkovic, B., Millot-Keurinck, J., Mlinarić, H., Momas, I., Montefort, S., Morais-Almeida, M., Moreno-Casbas, T., Mösges, R., Mullol, J., Nadif, R., Nalin, M., Navarro-Pardo, E., Nekam, K., Ninot, G., Paccard, D., Pais, S., Palummeri, E., Panzner, P., Papadopoulos, N. K., Papanikolaou, C., Passalacqua, G., Pastor, E., Perrot, M., Plavec, D., Popov, T. A., Postma, D. S., Price, D., Raffort, N., Reuzeau, J. C., Robine, J. M., Rodenas, F., Robusto, F., Roche, N., Romano, A., Romano, V., Rosado-Pinto, J., Roubille, F., Ruiz, F., Ryan, D., Salcedo, T., Schmid-Grendelmeier, P., Schulz, H., Schunemann, H. J., Serrano, E., Sheikh, A., Shields, M., Siafakas, N., Scichilone, N., Siciliano, P., Skrindo, I., Smit, H. A., Sourdet, S., Sousa-Costa, E., Spranger, O., Sooronbaev, T., Sruk, V., Sterk, P. J., Todo-Bom, A., Touchon, J., Tramontano, D., Triggiani, M., Tsartara, S. I., Valero, A. L., Valovirta, E., van Ganse, E., van Hage, M., van den Berge, M., Vandenplas, O., Ventura, M. T., Vergara, I., Vezzani, G., Vidal, D., Viegi, G., Wagemann, M., Whalley, B., Wickman, M., Wilson, N., Yiallouros, P. K., Žagar, M., Zaidi, A., Zidarn, M., Hoogerwerf, E. J., Usero, J., Zuffada, R., Senn, A., and de Oliveira-Alves, B.
- Published
- 2023
- Full Text
- View/download PDF
4. EUFOREA/EPOS2020 statement on the clinical considerations for CRSwNP care
- Author
-
Hellings, Peter W., primary, Alobid, Isam, additional, Anselmo‐Lima, Wilma T., additional, Bernal‐Sprekelsen, Manuel, additional, Bjermer, Leif, additional, Caulley, Lisa, additional, Chaker, Adam, additional, Constantinidis, Jannis, additional, Conti, Diego M., additional, De Corso, Eugenio, additional, Desrosiers, Martin, additional, Diamant, Zuzana, additional, Gevaert, Philippe, additional, Han, Joseph K., additional, Heffler, Enrico, additional, Hopkins, Claire, additional, Landis, Basile N., additional, Lourenco, Olga, additional, Lund, Valerie, additional, Luong, Amber U., additional, Mullol, Joaquim, additional, Peters, Anju, additional, Philpott, Carl, additional, Reitsma, Sietze, additional, Ryan, Dermot, additional, Scadding, Glenis, additional, Senior, Brent, additional, Tomazic, Peter Valentin, additional, Toskala, Elina, additional, Van Zele, Thibaut, additional, Viskens, An‐Sofie, additional, Wagenmann, Martin, additional, and Fokkens, W. J., additional
- Published
- 2023
- Full Text
- View/download PDF
5. EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP.
- Author
-
Fokkens, W. J., De Corso, E., Backer, V., Bernal-Sprekelsen, M., Bjermer, L., von Buchwald, C., Chaker, A., Diamant, Z., Gevaert, P., Han, J., Hopkins, C., Hox, V., Klimek, L., Lund, V. J., Lee, S., Luong, A., Mullol, J., Peters, A., Pfaar, O., and Reitsma, S.
- Published
- 2024
- Full Text
- View/download PDF
6. Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study
- Author
-
Sedaghat, A R, primary, Fokkens, W J, additional, Lund, V J, additional, Hellings, P W, additional, Kern, R C, additional, Reitsma, S, additional, Toppila-Salmi, S, additional, Bernal- Sprekelsen, M, additional, Mullol, J, additional, Gevaert, P, additional, Teeling, T, additional, Alobid, I, additional, Anselmo-Lima, W T, additional, Baroody, F M, additional, Cervin, A, additional, Cohen, N A, additional, Constantinidis, J, additional, De Gabory, L, additional, Desrosiers, M, additional, Harvey, R J, additional, Kalogjera, L, additional, Knill, A, additional, Landis, B N, additional, Meco, C, additional, Philpott, C M, additional, Ryan, D, additional, Schlosser, R J, additional, Senior, B A, additional, Smith, T L, additional, Tomazic, P V, additional, Zhang, L, additional, and Hopkins, C, additional
- Published
- 2023
- Full Text
- View/download PDF
7. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis
- Author
-
Bousquet, J., primary, Melén, E., additional, Haahtela, T., additional, Koppelman, G. H., additional, Togias, A., additional, Valenta, R., additional, Akdis, C. A., additional, Czarlewski, W., additional, Rothenberg, M., additional, Valiulis, A., additional, Wickman, M., additional, Akdis, M., additional, Aguilar, D., additional, Bedbrook, A., additional, Bindslev‐Jensen, C., additional, Bosnic‐Anticevich, S., additional, Boulet, L. P., additional, Brightling, C. E., additional, Brussino, L., additional, Burte, E., additional, Bustamante, M., additional, Canonica, G. W., additional, Cecchi, L., additional, Celedon, J. C., additional, Chaves Loureiro, C., additional, Costa, E., additional, Cruz, A. A., additional, Erhola, M., additional, Gemicioglu, B., additional, Fokkens, W. J., additional, Garcia‐Aymerich, J., additional, Guerra, S., additional, Heinrich, J., additional, Ivancevich, J. C., additional, Keil, T., additional, Klimek, L., additional, Kuna, P., additional, Kupczyk, M., additional, Kvedariene, V., additional, Larenas‐Linnemann, D. E., additional, Lemonnier, N., additional, Lodrup Carlsen, K. C., additional, Louis, R., additional, Makela, M., additional, Makris, M., additional, Maurer, M., additional, Momas, I., additional, Morais‐Almeida, M., additional, Mullol, J., additional, Naclerio, R. N., additional, Nadeau, K., additional, Nadif, R., additional, Niedoszytko, M., additional, Okamoto, Y., additional, Ollert, M., additional, Papadopoulos, N. G., additional, Passalacqua, G., additional, Patella, V., additional, Pawankar, R., additional, Pham‐Thi, N., additional, Pfaar, O., additional, Regateiro, F. S., additional, Ring, J., additional, Rouadi, P. W., additional, Samolinski, B., additional, Sastre, J., additional, Savouré, M., additional, Scichilone, N., additional, Shamji, M. H., additional, Sheikh, A., additional, Siroux, V., additional, Sousa‐Pinto, B., additional, Standl, M., additional, Sunyer, J., additional, Taborda‐Barata, L., additional, Toppila‐Salmi, S., additional, Torres, M. J., additional, Tsiligianni, I., additional, Valovirta, E., additional, Vandenplas, O., additional, Ventura, M. T., additional, Weiss, S., additional, Yorgancioglu, A., additional, Zhang, L., additional, Abdul Latiff, A. H., additional, Aberer, W., additional, Agache, I., additional, Al‐Ahmad, M., additional, Alobid, I., additional, Ansotegui, I. J., additional, Arshad, S. H., additional, Asayag, E., additional, Barbara, C., additional, Baharudin, A., additional, Battur, L., additional, Bennoor, K. S., additional, Berghea, E. C., additional, Bergmann, K. C., additional, Bernstein, D., additional, Bewick, M., additional, Blain, H., additional, Bonini, M., additional, Braido, F., additional, Buhl, R., additional, Bumbacea, R. S., additional, Bush, A., additional, Calderon, M., additional, Calvo‐Gil, M., additional, Camargos, P., additional, Caraballo, L., additional, Cardona, V., additional, Carr, W., additional, Carreiro‐Martins, P., additional, Casale, T., additional, Cepeda Sarabia, A. M., additional, Chandrasekharan, R., additional, Charpin, D., additional, Chen, Y. Z., additional, Cherrez‐Ojeda, I., additional, Chivato, T., additional, Chkhartishvili, E., additional, Christoff, G., additional, Chu, D. K., additional, Cingi, C., additional, Correia de Sousa, J., additional, Corrigan, C., additional, Custovic, A., additional, D’Amato, G., additional, Del Giacco, S., additional, De Blay, F., additional, Devillier, P., additional, Didier, A., additional, do Ceu Teixeira, M., additional, Dokic, D., additional, Douagui, H., additional, Doulaptsi, M., additional, Durham, S., additional, Dykewicz, M., additional, Eiwegger, T., additional, El‐Sayed, Z. A., additional, Emuzyte, R., additional, Fiocchi, A., additional, Fyhrquist, N., additional, Gomez, R. M., additional, Gotua, M., additional, Guzman, M. A., additional, Hagemann, J., additional, Hamamah, S., additional, Halken, S., additional, Halpin, D. M. G., additional, Hofmann, M., additional, Hossny, E., additional, Hrubiško, M., additional, Irani, C., additional, Ispayeva, Z., additional, Jares, E., additional, Jartti, T., additional, Jassem, E., additional, Julge, K., additional, Just, J., additional, Jutel, M., additional, Kaidashev, I., additional, Kalayci, O., additional, Kalyoncu, A. F., additional, Kardas, P., additional, Kirenga, B., additional, Kraxner, H., additional, Kull, I., additional, Kulus, M., additional, La Grutta, S., additional, Lau, S., additional, Le Tuyet Thi, L., additional, Levin, M., additional, Lipworth, B., additional, Lourenço, O., additional, Mahboub, B., additional, Martinez‐Infante, E., additional, Matricardi, P., additional, Miculinic, N., additional, Migueres, N., additional, Mihaltan, F., additional, Mohammad, Y., additional, Moniuszko, M., additional, Montefort, S., additional, Neffen, H., additional, Nekam, K., additional, Nunes, E., additional, Nyembue Tshipukane, D., additional, O’Hehir, R., additional, Ogulur, I., additional, Ohta, K., additional, Okubo, K., additional, Ouedraogo, S., additional, Olze, H., additional, Pali‐Schöll, I., additional, Palomares, O., additional, Palosuo, K., additional, Panaitescu, C., additional, Panzner, P., additional, Park, H. S., additional, Pitsios, C., additional, Plavec, D., additional, Popov, T. A., additional, Puggioni, F., additional, Quirce, S., additional, Recto, M., additional, Repka‐Ramirez, M. S., additional, Robalo Cordeiro, C., additional, Roche, N., additional, Rodriguez‐Gonzalez, M., additional, Romantowski, J., additional, Rosario Filho, N., additional, Rottem, M., additional, Sagara, H., additional, Serpa, F. S., additional, Sayah, Z., additional, Scheire, S., additional, Schmid‐Grendelmeier, P., additional, Sisul, J. C., additional, Sole, D., additional, Soto‐Martinez, M., additional, Sova, M., additional, Sperl, A., additional, Spranger, O., additional, Stelmach, R., additional, Suppli Ulrik, C., additional, Thomas, M., additional, To, T., additional, Todo‐Bom, A., additional, Tomazic, P. V., additional, Urrutia‐Pereira, M., additional, Valentin‐Rostan, M., additional, Van Ganse, E., additional, van Hage, M., additional, Vasankari, T., additional, Vichyanond, P., additional, Viegi, G., additional, Wallace, D., additional, Wang, D. Y., additional, Williams, S., additional, Worm, M., additional, Yiallouros, P., additional, Yusuf, O., additional, Zaitoun, F., additional, Zernotti, M., additional, Zidarn, M., additional, Zuberbier, J., additional, Fonseca, J. A., additional, Zuberbier, T., additional, and Anto, J. M., additional
- Published
- 2023
- Full Text
- View/download PDF
8. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023
- Author
-
Fokkens, W J, primary, Viskens, A-S, additional, Backer, V, additional, Conti, D, additional, De Corso, E, additional, Gevaert, P, additional, Scadding, G K, additional, Wagemann, M, additional, Bernal-Sprekelsen, M, additional, Chaker, A, additional, Heffler, E, additional, Han, J K, additional, Van Staeyen, E, additional, Hopkins, C, additional, Mullol, J, additional, Peters, A, additional, Reitsma, S, additional, Senior, B A, additional, and Hellings, P W, additional
- Published
- 2023
- Full Text
- View/download PDF
9. Rhinitis associated with asthma is distinct from rhinitis alone: The <scp>ARIA‐MeDALL</scp> hypothesis
- Author
-
UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J., Melén, E., Haahtela, T., Koppelman, G. H., Togias, A., Valenta, R., Akdis, C. A., Czarlewski, W., Rothenberg, M., Valiulis, A., Wickmann, M., Aguilar, D., Akdis, M., Ansotegui, I. J., Barbara, C., Bedbrook, A., Bindslev Jensen, C., Bosnic‐Anticevich, S., Boulet, L. P., Brightling, C. E., Brussino, L., Burte, E., Bustamante, M., Canonica, G. W., Cecchi, L., Celedon, J. C., Chaves‐Loureiro, C., Costa, E., Cruz, A. A., Erhola, M., Gemicioglu, B., Fokkens, W. J., Garcia Aymerich, J., Guerra, S., Heinrich, J., Ivancevich, J. C., Keil, T., Klimek, L., Kuna, P., Kupczyk, M., Kvedariene, V., Larenas‐Linnemann, D. E., Lemonnier, N., Lodrup Carlsen, K. C., Louis, R., Makris, M., Maurer, M., Momas, I., Morais‐Almeida, M., Mullol, J., Naclerio, R. N., Nadeau, K., Nadif, R., Niedoszytko, M., Okamoto, Y., Ollert, M., Papadopoulos, N. G., Passalacqua, G., Patella, V., Pawankar, R., Pham‐Thi, N., Pfaar, O., Regateiro, F. S., Ring, J., Rouadi, P. W., Samolinski, B., Sastre, J., Savouré, M., Scichilone, N., Shamji, M. H., Sheikh, A., Siroux, V., Sousa‐Pinto, B., Standl, M., Sunyer, J., Taborda‐Barata, L., Toppila‐Salmi, S., Torres, M. J., Tsiligianni, I., Valovirta, E., Vandenplas, Olivier, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bousquet, J., Melén, E., Haahtela, T., Koppelman, G. H., Togias, A., Valenta, R., Akdis, C. A., Czarlewski, W., Rothenberg, M., Valiulis, A., Wickmann, M., Aguilar, D., Akdis, M., Ansotegui, I. J., Barbara, C., Bedbrook, A., Bindslev Jensen, C., Bosnic‐Anticevich, S., Boulet, L. P., Brightling, C. E., Brussino, L., Burte, E., Bustamante, M., Canonica, G. W., Cecchi, L., Celedon, J. C., Chaves‐Loureiro, C., Costa, E., Cruz, A. A., Erhola, M., Gemicioglu, B., Fokkens, W. J., Garcia Aymerich, J., Guerra, S., Heinrich, J., Ivancevich, J. C., Keil, T., Klimek, L., Kuna, P., Kupczyk, M., Kvedariene, V., Larenas‐Linnemann, D. E., Lemonnier, N., Lodrup Carlsen, K. C., Louis, R., Makris, M., Maurer, M., Momas, I., Morais‐Almeida, M., Mullol, J., Naclerio, R. N., Nadeau, K., Nadif, R., Niedoszytko, M., Okamoto, Y., Ollert, M., Papadopoulos, N. G., Passalacqua, G., Patella, V., Pawankar, R., Pham‐Thi, N., Pfaar, O., Regateiro, F. S., Ring, J., Rouadi, P. W., Samolinski, B., Sastre, J., Savouré, M., Scichilone, N., Shamji, M. H., Sheikh, A., Siroux, V., Sousa‐Pinto, B., Standl, M., Sunyer, J., Taborda‐Barata, L., Toppila‐Salmi, S., Torres, M. J., Tsiligianni, I., Valovirta, E., and Vandenplas, Olivier
- Abstract
Asthma, rhinitis and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease", coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitisation and multimorbidity, (iii) advances in mHealth for novel phenotype definition, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut and neuropsychiatric multimorbidities, is the "Epithelial Barrier Hypothesis". This review determined that the "one-airway-one-disease" concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme "allergic" (asthma) phenotype combining asthma, rhinitis and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitisation patterns (mono- or pauci-sensitisation versus polysensitisation), (iii) severity of symptoms and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and auto-immune diseases.
- Published
- 2023
10. Rhinitis associated with asthma is distinct from rhinitis alone:The ARIA-MeDALL hypothesis
- Author
-
Bousquet, J, Melén, E, Haahtela, T, Koppelman, G H, Togias, A, Valenta, R, Akdis, C A, Czarlewski, W, Rothenberg, M, Valiulis, A, Wickman, M, Akdis, M, Aguilar, D, Bedbrook, A, Bindslev-Jensen, C, Bosnic-Anticevich, S, Boulet, L P, Brightling, C E, Brussino, L, Burte, E, Bustamante, M, Canonica, G W, Cecchi, L, Celedon, J C, Chaves Loureiro, C, Costa, E, Cruz, A A, Erhola, M, Gemicioglu, B, Fokkens, W J, Garcia-Aymerich, J, Guerra, S, Heinrich, J, Ivancevich, J C, Keil, T, Klimek, L, Kuna, P, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Lemonnier, N, Lodrup Carlsen, K C, Louis, R, Makela, M, Makris, M, Maurer, M, Momas, I, Morais-Almeida, M, Mullol, J, Naclerio, R N, Nadeau, K, Nadif, R, Niedoszytko, M, Okamoto, Y, Ollert, M, Papadopoulos, N G, Passalacqua, G, Patella, V, Pawankar, R, Pham-Thi, N, Pfaar, O, Regateiro, F S, Ring, J, Rouadi, P W, Samolinski, B, Sastre, J, Savouré, M, Scichilone, N, Shamji, M H, Sheikh, A, Siroux, V, Sousa-Pinto, B, Standl, M, Sunyer, J, Taborda-Barata, L, Toppila-Salmi, S, Torres, M J, Tsiligianni, I, Valovirta, E, Vandenplas, O, Ventura, M T, Weiss, S, Yorgancioglu, A, Zhang, L, Abdul Latiff, A H, Aberer, W, Agache, I, Al-Ahmad, M, Alobid, I, Ansotegui, I J, Arshad, S H, Asayag, E, Barbara, C, Baharudin, A, Battur, L, Bennoor, K S, Berghea, E C, Bergmann, K C, Bernstein, D, Bewick, M, Blain, H, Bonini, M, Braido, F, Buhl, R, Bumbacea, R S, Bush, A, Calderon, M, Calvo-Gil, M, Camargos, P, Caraballo, L, Cardona, V, Carr, W, Carreiro-Martins, P, Casale, T, Cepeda Sarabia, A M, Chandrasekharan, R, Charpin, D, Chen, Y Z, Cherrez-Ojeda, I, Chivato, T, Chkhartishvili, E, Christoff, G, Chu, D K, Cingi, C, Correia de Sousa, J, Corrigan, C, Custovic, A, D'Amato, G, Del Giacco, S, De Blay, F, Devillier, P, Didier, A, do Ceu Teixeira, M, Dokic, D, Douagui, H, Doulaptsi, M, Durham, S, Dykewicz, M, Eiwegger, T, El-Sayed, Z A, Emuzyte, R, Fiocchi, A, Fyhrquist, N, Gomez, R M, Gotua, M, Guzman, M A, Hagemann, J, Hamamah, S, Halken, S, Halpin, D M G, Hofmann, M, Hossny, E, Hrubiško, M, Irani, C, Ispayeva, Z, Jares, E, Jartti, T, Jassem, E, Julge, K, Just, J, Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, A F, Kardas, P, Kirenga, B, Kraxner, H, Kull, I, Kulus, M, La Grutta, S, Lau, S, Le Tuyet Thi, L, Levin, M, Lipworth, B, Lourenço, O, Mahboub, B, Martinez-Infante, E, Matricardi, P, Miculinic, N, Migueres, N, Mihaltan, F, Mohammad, Y, Moniuszko, M, Montefort, S, Neffen, H, Nekam, K, Nunes, E, Nyembue Tshipukane, D, O'Hehir, R, Ogulur, I, Ohta, K, Okubo, K, Ouedraogo, S, Olze, H, Pali-Schöll, I, Palomares, O, Palosuo, K, Panaitescu, C, Panzner, P, Park, H S, Pitsios, C, Plavec, D, Popov, T A, Puggioni, F, Quirce, S, Recto, M, Repka-Ramirez, M S, Robalo Cordeiro, C, Roche, N, Rodriguez-Gonzalez, M, Romantowski, J, Rosario Filho, N, Rottem, M, Sagara, H, Serpa, F S, Sayah, Z, Scheire, S, Schmid-Grendelmeier, P, Sisul, J C, Sole, D, Soto-Martinez, M, Sova, M, Sperl, A, Spranger, O, Stelmach, R, Suppli Ulrik, C, Thomas, M, To, T, Todo-Bom, A, Tomazic, P V, Urrutia-Pereira, M, Valentin-Rostan, M, Van Ganse, E, van Hage, M, Vasankari, T, Vichyanond, P, Viegi, G, Wallace, D, Wang, D Y, Williams, S, Worm, M, Yiallouros, P, Yusuf, O, Zaitoun, F, Zernotti, M, Zidarn, M, Zuberbier, J, Fonseca, J A, Zuberbier, T, Anto, J M, Bousquet, J, Melén, E, Haahtela, T, Koppelman, G H, Togias, A, Valenta, R, Akdis, C A, Czarlewski, W, Rothenberg, M, Valiulis, A, Wickman, M, Akdis, M, Aguilar, D, Bedbrook, A, Bindslev-Jensen, C, Bosnic-Anticevich, S, Boulet, L P, Brightling, C E, Brussino, L, Burte, E, Bustamante, M, Canonica, G W, Cecchi, L, Celedon, J C, Chaves Loureiro, C, Costa, E, Cruz, A A, Erhola, M, Gemicioglu, B, Fokkens, W J, Garcia-Aymerich, J, Guerra, S, Heinrich, J, Ivancevich, J C, Keil, T, Klimek, L, Kuna, P, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Lemonnier, N, Lodrup Carlsen, K C, Louis, R, Makela, M, Makris, M, Maurer, M, Momas, I, Morais-Almeida, M, Mullol, J, Naclerio, R N, Nadeau, K, Nadif, R, Niedoszytko, M, Okamoto, Y, Ollert, M, Papadopoulos, N G, Passalacqua, G, Patella, V, Pawankar, R, Pham-Thi, N, Pfaar, O, Regateiro, F S, Ring, J, Rouadi, P W, Samolinski, B, Sastre, J, Savouré, M, Scichilone, N, Shamji, M H, Sheikh, A, Siroux, V, Sousa-Pinto, B, Standl, M, Sunyer, J, Taborda-Barata, L, Toppila-Salmi, S, Torres, M J, Tsiligianni, I, Valovirta, E, Vandenplas, O, Ventura, M T, Weiss, S, Yorgancioglu, A, Zhang, L, Abdul Latiff, A H, Aberer, W, Agache, I, Al-Ahmad, M, Alobid, I, Ansotegui, I J, Arshad, S H, Asayag, E, Barbara, C, Baharudin, A, Battur, L, Bennoor, K S, Berghea, E C, Bergmann, K C, Bernstein, D, Bewick, M, Blain, H, Bonini, M, Braido, F, Buhl, R, Bumbacea, R S, Bush, A, Calderon, M, Calvo-Gil, M, Camargos, P, Caraballo, L, Cardona, V, Carr, W, Carreiro-Martins, P, Casale, T, Cepeda Sarabia, A M, Chandrasekharan, R, Charpin, D, Chen, Y Z, Cherrez-Ojeda, I, Chivato, T, Chkhartishvili, E, Christoff, G, Chu, D K, Cingi, C, Correia de Sousa, J, Corrigan, C, Custovic, A, D'Amato, G, Del Giacco, S, De Blay, F, Devillier, P, Didier, A, do Ceu Teixeira, M, Dokic, D, Douagui, H, Doulaptsi, M, Durham, S, Dykewicz, M, Eiwegger, T, El-Sayed, Z A, Emuzyte, R, Fiocchi, A, Fyhrquist, N, Gomez, R M, Gotua, M, Guzman, M A, Hagemann, J, Hamamah, S, Halken, S, Halpin, D M G, Hofmann, M, Hossny, E, Hrubiško, M, Irani, C, Ispayeva, Z, Jares, E, Jartti, T, Jassem, E, Julge, K, Just, J, Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, A F, Kardas, P, Kirenga, B, Kraxner, H, Kull, I, Kulus, M, La Grutta, S, Lau, S, Le Tuyet Thi, L, Levin, M, Lipworth, B, Lourenço, O, Mahboub, B, Martinez-Infante, E, Matricardi, P, Miculinic, N, Migueres, N, Mihaltan, F, Mohammad, Y, Moniuszko, M, Montefort, S, Neffen, H, Nekam, K, Nunes, E, Nyembue Tshipukane, D, O'Hehir, R, Ogulur, I, Ohta, K, Okubo, K, Ouedraogo, S, Olze, H, Pali-Schöll, I, Palomares, O, Palosuo, K, Panaitescu, C, Panzner, P, Park, H S, Pitsios, C, Plavec, D, Popov, T A, Puggioni, F, Quirce, S, Recto, M, Repka-Ramirez, M S, Robalo Cordeiro, C, Roche, N, Rodriguez-Gonzalez, M, Romantowski, J, Rosario Filho, N, Rottem, M, Sagara, H, Serpa, F S, Sayah, Z, Scheire, S, Schmid-Grendelmeier, P, Sisul, J C, Sole, D, Soto-Martinez, M, Sova, M, Sperl, A, Spranger, O, Stelmach, R, Suppli Ulrik, C, Thomas, M, To, T, Todo-Bom, A, Tomazic, P V, Urrutia-Pereira, M, Valentin-Rostan, M, Van Ganse, E, van Hage, M, Vasankari, T, Vichyanond, P, Viegi, G, Wallace, D, Wang, D Y, Williams, S, Worm, M, Yiallouros, P, Yusuf, O, Zaitoun, F, Zernotti, M, Zidarn, M, Zuberbier, J, Fonseca, J A, Zuberbier, T, and Anto, J M
- Abstract
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one-airway-one-disease,” coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one-airway-one-disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases., Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease," coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the "Epithelial Barrier Hypothesis." This review determined that the "one-airway-one-disease" concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme "allergic" (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.
- Published
- 2023
11. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis
- Author
-
Bousquet, J, Melén, E, Haahtela, T, Koppelman, G H, Togias, A, Valenta, R, Akdis, C A, Czarlewski, W, Rothenberg, M, Valiulis, A, Wickmann, M, Aguilar, D, Akdis, M, Ansotegui, I J, Barbara, C, Bedbrook, A, Bindslev Jensen, C, Bosnic-Anticevich, S, Boulet, L P, Brightling, C E, Brussino, L, Burte, E, Bustamante, M, Canonica, G W, Cecchi, L, Celedon, J C, Chaves-Loureiro, C, Costa, E, Cruz, A A, Erhola, M, Gemicioglu, B, Fokkens, W J, Garcia Aymerich, J, Guerra, S, Heinrich, J, Ivancevich, J C, Keil, T, Klimek, L, Kuna, P, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Lemonnier, N, Lodrup Carlsen, K C, Louis, R, Makris, M, Maurer, M, Momas, I, Morais-Almeida, M, Mullol, J, Naclerio, R N, Nadeau, K, Nadif, R, Niedoszytko, M, Okamoto, Y, Ollert, M, Papadopoulos, N G, Passalacqua, G, Patella, V, Pawankar, R, Pham-Thi, N, Pfaar, O, Regateiro, F S, Ring, J, Rouadi, P W, Samolinski, B, Sastre, J, Savouré, M, Scichilone, N, Shamji, M H, Sheikh, A, Siroux, V, Sousa-Pinto, B, Standl, M, Sunyer, J, Taborda-Barata, L, Toppila-Salmi, S, Torres, M J, Tsiligianni, I, Valovirta, E, Vandenplas, O, Ventura, M T, Weiss, S, Yorgancioglu, A, Zhang, L, Abdul Latiff, A H, Aberer, W, Agache, I, Al-Ahmad, M, Alobid, I, Arshad, H S, Asayag, E, Baharudin, A, Battur, L, Bennoor, K S, Berghea, E C, Bergmann, K C, Bernstein, D, Bewick, Michael, Blain, H, Bonini, M, Braido, F, Buhl, R, Bumbacea, R, Bush, A, Calderon, M, Calvo, G, Camargos, P, Caraballo, L, Cardona, V, Carr, W, Carreiro-Martins, P, Casale, T, Cepeda Sarabia, A M, Chandrasekharan, R, Charpin, D, Chen, Y Z, Cherrez-Ojeda, I, Chivato, T, Chkhartishvili, E, Christoff, G, Chu, D K, Cingi, C, Correia da Sousa, J, Corrigan, C, Custovic, A, D'Amato, G, Del Giacco, S, De Blay, F, Devillier, P, Didier, A, do Ceu Teixeira, M, Dokic, D, Douagui, H, Doulaptsi, M, Durham, S, Dykewicz, M, Eiwegger, T, El-Sayed, Z A, Emuzyte, R, Fiocchi, A, Fyhrquist, N, Gomez, R M, Gotua, M, Guzman, M A, Hagemann, J, Hamamah, S, Halken, S, Halpin, D M G, Hofmann, M, Hossny, E, Hrubiško, M, Irani, C, Ispayeva, Z, Jares, E, Jartti, T, Jassem, E, Julge, K, Just, J, Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, O, Kardas, P, Kirenga, B, Kraxner, H, Kull, I, Kulus, M, La Gruta, S, Lau, S, Le Tuyet Thi, L, Levin, M, Lipworth, B, Lourenço, O, Mahboub, B, Mäkelä, M J, Martinez-Infante, E, Matricardi, P, Miculinic, N, Migueres, N, Mihaltan, F, Mohamad, Y, Moniusko, M, Montefort, S, Neffen, H, Nekam, K, Nunes, E, Nyembue Tshipukane, D, O'Hehir, R E, Ogulur, I, Ohta, K, Okubo, K, Ouedraogo, S, Olze, H, Pali-Schöll, I, Palomares, O, Palosuo, K, Panaitescu, C, Panzner, P, Park, H S, Pitsios, C, Plavec, D, Popov, T A, Puggioni, F, Quirce, S, Recto, M, Repka-Ramirez, R, Roballo-Cordeiro, C, Roche, N, Rodriguez-Gonzales, M, Romantowski, J, Rosario Filho, N, Rottem, M, Sagara, H, Sarquis-Serpa, F, Sayah, Z, Scheire, S, Schmid-Grendelmeier, P, Sisul, J C, Sole, D, Soto-Martinez, M, Sova, M, Sperl, A, Spranger, O, Stelmach, R, Suppli Ulrik, C, Thomas, M, To, T, Todo-Bom, A, Tomazic, P V, Urrutia-Pereira, M, Valentin-Rostan, M, van Ganse, E, Van Hage, M, Vasankari, T, Vichyanond, P, Viegi, G, Wallace, D, Wang, D Y, Williams, S, Worm, M, Yiallouros, P, Yusuf, O, Zaitoun, F, Zernotti, M, Zidarn, M, Zuberbier, J, Fonseca, J A, Zuberbier, T, Anto, J M, Bousquet, J, Melén, E, Haahtela, T, Koppelman, G H, Togias, A, Valenta, R, Akdis, C A, Czarlewski, W, Rothenberg, M, Valiulis, A, Wickmann, M, Aguilar, D, Akdis, M, Ansotegui, I J, Barbara, C, Bedbrook, A, Bindslev Jensen, C, Bosnic-Anticevich, S, Boulet, L P, Brightling, C E, Brussino, L, Burte, E, Bustamante, M, Canonica, G W, Cecchi, L, Celedon, J C, Chaves-Loureiro, C, Costa, E, Cruz, A A, Erhola, M, Gemicioglu, B, Fokkens, W J, Garcia Aymerich, J, Guerra, S, Heinrich, J, Ivancevich, J C, Keil, T, Klimek, L, Kuna, P, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Lemonnier, N, Lodrup Carlsen, K C, Louis, R, Makris, M, Maurer, M, Momas, I, Morais-Almeida, M, Mullol, J, Naclerio, R N, Nadeau, K, Nadif, R, Niedoszytko, M, Okamoto, Y, Ollert, M, Papadopoulos, N G, Passalacqua, G, Patella, V, Pawankar, R, Pham-Thi, N, Pfaar, O, Regateiro, F S, Ring, J, Rouadi, P W, Samolinski, B, Sastre, J, Savouré, M, Scichilone, N, Shamji, M H, Sheikh, A, Siroux, V, Sousa-Pinto, B, Standl, M, Sunyer, J, Taborda-Barata, L, Toppila-Salmi, S, Torres, M J, Tsiligianni, I, Valovirta, E, Vandenplas, O, Ventura, M T, Weiss, S, Yorgancioglu, A, Zhang, L, Abdul Latiff, A H, Aberer, W, Agache, I, Al-Ahmad, M, Alobid, I, Arshad, H S, Asayag, E, Baharudin, A, Battur, L, Bennoor, K S, Berghea, E C, Bergmann, K C, Bernstein, D, Bewick, Michael, Blain, H, Bonini, M, Braido, F, Buhl, R, Bumbacea, R, Bush, A, Calderon, M, Calvo, G, Camargos, P, Caraballo, L, Cardona, V, Carr, W, Carreiro-Martins, P, Casale, T, Cepeda Sarabia, A M, Chandrasekharan, R, Charpin, D, Chen, Y Z, Cherrez-Ojeda, I, Chivato, T, Chkhartishvili, E, Christoff, G, Chu, D K, Cingi, C, Correia da Sousa, J, Corrigan, C, Custovic, A, D'Amato, G, Del Giacco, S, De Blay, F, Devillier, P, Didier, A, do Ceu Teixeira, M, Dokic, D, Douagui, H, Doulaptsi, M, Durham, S, Dykewicz, M, Eiwegger, T, El-Sayed, Z A, Emuzyte, R, Fiocchi, A, Fyhrquist, N, Gomez, R M, Gotua, M, Guzman, M A, Hagemann, J, Hamamah, S, Halken, S, Halpin, D M G, Hofmann, M, Hossny, E, Hrubiško, M, Irani, C, Ispayeva, Z, Jares, E, Jartti, T, Jassem, E, Julge, K, Just, J, Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, O, Kardas, P, Kirenga, B, Kraxner, H, Kull, I, Kulus, M, La Gruta, S, Lau, S, Le Tuyet Thi, L, Levin, M, Lipworth, B, Lourenço, O, Mahboub, B, Mäkelä, M J, Martinez-Infante, E, Matricardi, P, Miculinic, N, Migueres, N, Mihaltan, F, Mohamad, Y, Moniusko, M, Montefort, S, Neffen, H, Nekam, K, Nunes, E, Nyembue Tshipukane, D, O'Hehir, R E, Ogulur, I, Ohta, K, Okubo, K, Ouedraogo, S, Olze, H, Pali-Schöll, I, Palomares, O, Palosuo, K, Panaitescu, C, Panzner, P, Park, H S, Pitsios, C, Plavec, D, Popov, T A, Puggioni, F, Quirce, S, Recto, M, Repka-Ramirez, R, Roballo-Cordeiro, C, Roche, N, Rodriguez-Gonzales, M, Romantowski, J, Rosario Filho, N, Rottem, M, Sagara, H, Sarquis-Serpa, F, Sayah, Z, Scheire, S, Schmid-Grendelmeier, P, Sisul, J C, Sole, D, Soto-Martinez, M, Sova, M, Sperl, A, Spranger, O, Stelmach, R, Suppli Ulrik, C, Thomas, M, To, T, Todo-Bom, A, Tomazic, P V, Urrutia-Pereira, M, Valentin-Rostan, M, van Ganse, E, Van Hage, M, Vasankari, T, Vichyanond, P, Viegi, G, Wallace, D, Wang, D Y, Williams, S, Worm, M, Yiallouros, P, Yusuf, O, Zaitoun, F, Zernotti, M, Zidarn, M, Zuberbier, J, Fonseca, J A, Zuberbier, T, and Anto, J M
- Abstract
Asthma, rhinitis and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease", coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitisation and multimorbidity, (iii) advances in mHealth for novel phenotype definition, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut and neuropsychiatric multimorbidities, is the "Epithelial Barrier Hypothesis". This review determined that the "one-airway-one-disease" concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme "allergic" (asthma) phenotype combining asthma, rhinitis and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitisation patterns (mono- or pauci-sensitisation versus polysensitisation), (iii) severity of symptoms and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and auto-immune diseases. [Abstract copyright: This article is protected by copyright. All rights reserved.]
- Published
- 2023
12. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA‐MeDALL hypothesis
- Author
-
Bousquet, J; https://orcid.org/0000-0002-4061-4766, Melén, E; https://orcid.org/0000-0002-8248-0663, Haahtela, T; https://orcid.org/0000-0003-4757-2156, Koppelman, G H; https://orcid.org/0000-0001-8567-3252, Togias, A; https://orcid.org/0000-0001-9009-5717, Valenta, R; https://orcid.org/0000-0001-5944-3365, Akdis, C A; https://orcid.org/0000-0001-8020-019X, Czarlewski, W; https://orcid.org/0000-0002-6180-3232, Rothenberg, M; https://orcid.org/0000-0001-9790-6332, Valiulis, A; https://orcid.org/0000-0002-0287-9915, Wickman, M; https://orcid.org/0000-0003-2710-8620, Akdis, M; https://orcid.org/0000-0003-0554-9943, Aguilar, D; https://orcid.org/0000-0001-5399-3278, Bedbrook, A; https://orcid.org/0000-0001-9226-7762, Bindslev‐Jensen, C; https://orcid.org/0000-0002-8940-038X, Bosnic‐Anticevich, S; https://orcid.org/0000-0001-5077-8329, Boulet, L P; https://orcid.org/0000-0003-3485-9393, Brightling, C E; https://orcid.org/0000-0002-9345-4903, Brussino, L; https://orcid.org/0000-0001-7249-7616, Burte, E; https://orcid.org/0000-0003-3341-5352, Bustamante, M; https://orcid.org/0000-0003-0127-2860, Canonica, G W; https://orcid.org/0000-0001-8467-2557, Cecchi, L; https://orcid.org/0000-0002-0658-2449, Celedon, J C; https://orcid.org/0000-0001-7676-4478, Chaves Loureiro, C; https://orcid.org/0000-0003-0438-6126, Costa, E; https://orcid.org/0000-0003-1158-1480, Cruz, A A; https://orcid.org/0000-0002-7403-3871, Erhola, M; https://orcid.org/0000-0002-1364-9023, Gemicioglu, B; https://orcid.org/0000-0001-5953-4881, Fokkens, W J; https://orcid.org/0000-0003-4852-229X, et al, Schmid-Grendelmeier, P; https://orcid.org/0000-0003-3215-3370, Bousquet, J; https://orcid.org/0000-0002-4061-4766, Melén, E; https://orcid.org/0000-0002-8248-0663, Haahtela, T; https://orcid.org/0000-0003-4757-2156, Koppelman, G H; https://orcid.org/0000-0001-8567-3252, Togias, A; https://orcid.org/0000-0001-9009-5717, Valenta, R; https://orcid.org/0000-0001-5944-3365, Akdis, C A; https://orcid.org/0000-0001-8020-019X, Czarlewski, W; https://orcid.org/0000-0002-6180-3232, Rothenberg, M; https://orcid.org/0000-0001-9790-6332, Valiulis, A; https://orcid.org/0000-0002-0287-9915, Wickman, M; https://orcid.org/0000-0003-2710-8620, Akdis, M; https://orcid.org/0000-0003-0554-9943, Aguilar, D; https://orcid.org/0000-0001-5399-3278, Bedbrook, A; https://orcid.org/0000-0001-9226-7762, Bindslev‐Jensen, C; https://orcid.org/0000-0002-8940-038X, Bosnic‐Anticevich, S; https://orcid.org/0000-0001-5077-8329, Boulet, L P; https://orcid.org/0000-0003-3485-9393, Brightling, C E; https://orcid.org/0000-0002-9345-4903, Brussino, L; https://orcid.org/0000-0001-7249-7616, Burte, E; https://orcid.org/0000-0003-3341-5352, Bustamante, M; https://orcid.org/0000-0003-0127-2860, Canonica, G W; https://orcid.org/0000-0001-8467-2557, Cecchi, L; https://orcid.org/0000-0002-0658-2449, Celedon, J C; https://orcid.org/0000-0001-7676-4478, Chaves Loureiro, C; https://orcid.org/0000-0003-0438-6126, Costa, E; https://orcid.org/0000-0003-1158-1480, Cruz, A A; https://orcid.org/0000-0002-7403-3871, Erhola, M; https://orcid.org/0000-0002-1364-9023, Gemicioglu, B; https://orcid.org/0000-0001-5953-4881, Fokkens, W J; https://orcid.org/0000-0003-4852-229X, et al, and Schmid-Grendelmeier, P; https://orcid.org/0000-0003-3215-3370
- Abstract
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of “one‐airway‐one‐disease,” coined over 20 years ago, is a simplistic approach of the links between upper‐ and lower‐airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper‐ and lower‐airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the “Epithelial Barrier Hypothesis.” This review determined that the “one‐airway‐one‐disease” concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme “allergic” (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll‐Like Receptors and IL‐17 for rhinitis alone as a local disease; IL‐33 and IL‐5 for allergic and non‐allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono‐ or pauci‐sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases.
- Published
- 2023
13. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023
- Author
-
Fokkens, W. J., Viskens, An Sofie, Backer, Vibeke, Conti, Diego, de Corso, Eugenio, Gevaert, Philippe, Scadding, Glenis K., Wagemann, Martin, Sprekelsen, Manuel Bernal, Chaker, Adam, Heffler, Enrico, Han, Joseph K., Staeyen, Elizabeth Van, Hopkins, Claire, Mullol, Joaquim, Peters, Anju, Reitsma, Sietze, Senior, Brent A., Hellings, Peter W., Fokkens, W. J., Viskens, An Sofie, Backer, Vibeke, Conti, Diego, de Corso, Eugenio, Gevaert, Philippe, Scadding, Glenis K., Wagemann, Martin, Sprekelsen, Manuel Bernal, Chaker, Adam, Heffler, Enrico, Han, Joseph K., Staeyen, Elizabeth Van, Hopkins, Claire, Mullol, Joaquim, Peters, Anju, Reitsma, Sietze, Senior, Brent A., and Hellings, Peter W.
- Abstract
Severe chronic rhinosinusitis with nasal polyps (CRSwNP) is a debilitating disease with a significant impact on the quality of life (QoL). It is typically characterized by a type 2 inflammatory reaction and by comorbidities such as asthma, allergies and NSAID-Exacerbated Respiratory Disease (N-ERD). Here, the European Forum for Research and Education in Allergy and Airway diseases discusses practical guidelines for patients on biologic treatment. Criteria for the selection of patients who would benefit from biologics were updated. Guidelines are proposed concerning the monitoring of the drug effects that provide recognition of res-ponders to the therapy and, subsequently, the decision about continuation, switching or discontinuation of a biologic. Further-more, gaps in the current knowledge and unmet needs were discussed.
- Published
- 2023
14. The ARIA-MeDALL hypothesis
- Author
-
Bousquet, J, Melén, E, Haahtela, T, Koppelman, G H, Togias, A, Valenta, R, Akdis, C A, Czarlewski, W, Rothenberg, M, Valiulis, A, Wickmann, M, Bonini, M, Braido, F, Buhl, R, Bumbacea, R, Bush, A, Calderon, M, Calvo, G, Camargos, P, Caraballo, L, Cardona, V, Aguilar, D, Carr, W, Carreiro-Martins, P, Casale, T, Cepeda Sarabia, A M, Chandrasekharan, R, Charpin, D, Chen, Y Z, Cherrez-Ojeda, I, Chivato, T, Chkhartishvili, E, Akdis, M, Christoff, G, Chu, D K, Cingi, C, Correia da Sousa, J, Corrigan, C, Custovic, A, D'Amato, G, Del Giacco, S, De Blay, F, Devillier, P, Ansotegui, I J, Didier, A, do Ceu Teixeira, M, Dokic, D, Douagui, H, Doulaptsi, M, Durham, S, Dykewicz, M, Eiwegger, T, El-Sayed, Z A, Emuzyte, R, Barbara, C, Fiocchi, A, Fyhrquist, N, Gomez, R M, Gotua, M, Guzman, M A, Hagemann, J, Hamamah, S, Halken, S, Halpin, D M G, Bedbrook, A, Hofmann, M, Hossny, E, Hrubiško, M, Irani, C, Ispayeva, Z, Jares, E, Jartti, T, Jassem, E, Julge, K, Just, J, Bindslev Jensen, C, Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, O, Kardas, P, Kirenga, B, Kraxner, H, Kull, I, Kulus, M, La Gruta, S, Bosnic-Anticevich, S, Lau, S, Le Tuyet Thi, L, Levin, M, Lipworth, B, Lourenço, O, Mahboub, B, Mäkelä, M J, Martinez-Infante, E, Matricardi, P, Miculinic, N, Boulet, L P, Migueres, N, Mihaltan, F, Mohamad, Y, Moniusko, M, Montefort, S, Neffen, H, Nekam, K, Nunes, E, Nyembue Tshipukane, D, O'Hehir, R E, Brightling, C E, Ogulur, I, Ohta, K, Okubo, K, Ouedraogo, S, Olze, H, Pali-Schöll, I, Palomares, O, Palosuo, K, Panaitescu, C, Panzner, P, Brussino, L, Park, H S, Pitsios, C, Plavec, D, Popov, T A, Puggioni, F, Quirce, S, Recto, M, Repka-Ramirez, R, Roballo-Cordeiro, C, Roche, N, Burte, E, Rodriguez-Gonzales, M, Romantowski, J, Rosario Filho, N, Rottem, M, Sagara, H, Sarquis-Serpa, F, Sayah, Z, Scheire, S, Schmid-Grendelmeier, P, Sisul, J C, Bustamante, M, Sole, D, Soto-Martinez, M, Sova, M, Sperl, A, Spranger, O, Stelmach, R, Suppli Ulrik, C, Thomas, M, To, T, Todo-Bom, A, Canonica, G W, Tomazic, P V, Urrutia-Pereira, M, Valentin-Rostan, M, van Ganse, E, Van Hage, M, Vasankari, T, Vichyanond, P, Viegi, G, Wallace, D, Wang, D Y, Cecchi, L, Williams, S, Worm, M, Yiallouros, P, Yusuf, O, Zaitoun, F, Zernotti, M, Zidarn, M, Zuberbier, J, Fonseca, J A, Celedon, J C, Zuberbier, T, Anto, J M, Chaves-Loureiro, C, Costa, E, Cruz, A A, Erhola, M, Gemicioglu, B, Fokkens, W J, Garcia Aymerich, J, Guerra, S, Heinrich, J, Ivancevich, J C, Keil, T, Klimek, L, Kuna, P, Kupczyk, M, Kvedariene, V, Larenas-Linnemann, D E, Lemonnier, N, Lodrup Carlsen, K C, Louis, R, Makris, M, Maurer, M, Momas, I, Morais-Almeida, M, Mullol, J, Naclerio, R N, Nadeau, K, Nadif, R, Niedoszytko, M, Okamoto, Y, Ollert, M, Papadopoulos, N G, Passalacqua, G, Patella, V, Pawankar, R, Pham-Thi, N, Pfaar, O, Regateiro, F S, Ring, J, Rouadi, P W, Samolinski, B, Sastre, J, Savouré, M, Scichilone, N, Shamji, M H, Sheikh, A, Siroux, V, Sousa-Pinto, B, Standl, M, Sunyer, J, Taborda-Barata, L, Toppila-Salmi, S, Torres, M J, Tsiligianni, I, Valovirta, E, Vandenplas, O, Ventura, M T, Weiss, S, Yorgancioglu, A, Zhang, L, Abdul Latiff, A H, Aberer, W, Agache, I, Al-Ahmad, M, Alobid, I, Arshad, H S, Asayag, E, Baharudin, A, Battur, L, Bennoor, K S, Berghea, E C, Bergmann, K C, Bernstein, D, Bewick, M, Blain, H, UCIBIO - Applied Molecular Biosciences Unit, Comprehensive Health Research Centre (CHRC) - pólo NMS, and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
- Subjects
SDG 3 - Good Health and Well-being - Abstract
Asthma, rhinitis and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease", coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitisation and multimorbidity, (iii) advances in mHealth for novel phenotype definition, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut and neuropsychiatric multimorbidities, is the "Epithelial Barrier Hypothesis". This review determined that the "one-airway-one-disease" concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme "allergic" (asthma) phenotype combining asthma, rhinitis and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitisation patterns (mono- or pauci-sensitisation versus polysensitisation), (iii) severity of symptoms and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and auto-immune diseases. authorsversion epub_ahead_of_print
- Published
- 2023
15. Additional file 1 of Association between outdoor air pollution and chronic rhinosinusitis patient reported outcomes
- Author
-
Peeters, S., Wang, C., Bijnens, E. M., Bullens, D. M. A., Fokkens, W. J., Bachert, C., Hellings, P. W., Nawrot, T. S., and Seys, S. F.
- Abstract
Additional file 1: Figure S1. Workflow depicting hierarchical model build-up and selection process. Figure S2. Variation in VAS of the total CRS symptoms per month. Figure S3. Relationship between CRS symptom severity and outdoor air pollution for the spring-summer population. Figure S4. Relationship between CRS symptom severity and outdoor air pollution for the fall - winter population. Table S1. Spearman’s rank correlation for same pollutants on adjacent lag days. Table S2. Spearman’s rank correlation for different pollutants on lag day 0. Table S3. AIC for model selection of the adjusted spring-summer population.
- Published
- 2023
- Full Text
- View/download PDF
16. Measuring control of disease in Chronic Rhinosinusitis; assessing the correlation between SinoNasal Outcome Test-22 and Visual Analogue Scale item scores.
- Author
-
de Loos, D. A. E. Dietz, Cornet, M. E., Hopkins, C., Fokkens, W. J., and Reitsma, S.
- Published
- 2023
- Full Text
- View/download PDF
17. The EUFOREA pocket guide for chronic rhinosinusitis.
- Author
-
Hellings, P. W., Fokkens, W. J., Orlandi, R., Adriaensen, G. F., Alobid, I., Baroody, F. M., Bjermer, L., Senior, B. A., Cervin, A., Cohen, N. A., Constantinidis, J., De Corso, E., Desrosiers, M., Diamant, Z., Douglas, R. G., Gane, S., Gevaert, P., Han, J. K., Harvey, R. J., and Hopkins, C.
- Published
- 2023
- Full Text
- View/download PDF
18. Development and validation of combined symptom-medication scores for allergic rhinitis*
- Author
-
Bernardo Sousa‐Pinto, Luís Filipe Azevedo, Marek Jutel, Ioana Agache, G. Walter Canonica, Wienczyslawa Czarlewski, Nikolaos G. Papadopoulos, Karl‐Christian Bergmann, Philippe Devillier, Daniel Laune, Ludger Klimek, Aram Anto, Josep M. Anto, Patrik Eklund, Rute Almeida, Anna Bedbrook, Sinthia Bosnic‐Anticevich, Helen A. Brough, Luisa Brussino, Victoria Cardona, Thomas Casale, Lorenzo Cecchi, Denis Charpin, Tomás Chivato, Elisio M. Costa, Alvaro A. Cruz, Stephanie Dramburg, Stephen R. Durham, Giulia De Feo, Roy Gerth van Wijk, Wystke J. Fokkens, Bilun Gemicioglu, Tari Haahtela, Maddalena Illario, Juan Carlos Ivancevich, Violeta Kvedariene, Piotr Kuna, Désirée E. Larenas‐Linnemann, Michael Makris, Eve Mathieu‐Dupas, Erik Melén, Mario Morais‐Almeida, Ralph Mösges, Joaquim Mullol, Kari C. Nadeau, Nhân Pham‐Thi, Robyn O’Hehir, Frederico S. Regateiro, Sietze Reitsma, Boleslaw Samolinski, Aziz Sheikh, Cristiana Stellato, Ana Todo‐Bom, Peter Valentin Tomazic, Sanna Toppila‐Salmi, Antonio Valero, Arunas Valiulis, Maria Teresa Ventura, Dana Wallace, Susan Waserman, Arzu Yorgancioglu, Govert De Vries, Michiel van Eerd, Petra Zieglmayer, Torsten Zuberbier, Oliver Pfaar, João Almeida Fonseca, Jean Bousquet, Internal Medicine, HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, University of Helsinki, Ear, Nose and Throat, AII - Inflammatory diseases, Publica, Sousa-Pinto, B., Azevedo, L. F., Jutel, M., Agache, I., Canonica, G. W., Czarlewski, W., Papadopoulos, N. G., Bergmann, K. -C., Devillier, P., Laune, D., Klimek, L., Anto, A., Anto, J. M., Eklund, P., Almeida, R., Bedbrook, A., Bosnic-Anticevich, S., Brough, H. A., Brussino, L., Cardona, V., Casale, T., Cecchi, L., Charpin, D., Chivato, T., Costa, E. M., Cruz, A. A., Dramburg, S., Durham, S. R., De Feo, G., Gerth van Wijk, R., Fokkens, W. J., Gemicioglu, B., Haahtela, T., Illario, M., Ivancevich, J. C., Kvedariene, V., Kuna, P., Larenas-Linnemann, D. E., Makris, M., Mathieu-Dupas, E., Melen, E., Morais-Almeida, M., Mosges, R., Mullol, J., Nadeau, K. C., Pham-Thi, N., O'Hehir, R., Regateiro, F. S., Reitsma, S., Samolinski, B., Sheikh, A., Stellato, Cristiana, Todo-Bom, A., Tomazic, P. V., Toppila-Salmi, S., Valero, A., Valiulis, A., Ventura, M. T., Wallace, D., Waserman, S., Yorgancioglu, A., De Vries, G., van Eerd, M., Zieglmayer, P., Zuberbier, T., Pfaar, O., Almeida Fonseca, J., and Bousquet, J.
- Subjects
Work ,medication score ,quality-of-life ,rhinitis ,symptom score ,work ,Respiratory Medicine and Allergy ,Immunology ,QUESTIONNAIRE ,RESPONSIVENESS ,Humans ,Immunology and Allergy ,IMMUNOTHERAPY ,VALIDITY ,Lungmedicin och allergi ,Rhinitis ,Medication score ,EQ-5D ,Reproducibility of Results ,IMPAIRMENT ,Rhinitis, Allergic ,WORK PRODUCTIVITY ,Symptom score ,rhiniti ,TRIALS ,3121 General medicine, internal medicine and other clinical medicine ,RELIABILITY ,Quality of Life ,ASTHMA ,Quality-of-life ,600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit - Abstract
Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air® app to generate and validate hypothesis- and data-driven CSMSs. Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air®, and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT]). Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820). Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials.
- Published
- 2022
19. Recent advances in chronic rhinosinusitis: pathophysiology, treatments, and outcome measures.
- Author
-
Fokkens WJ, Sedaghat AR, Soyka MB, and Reitsma S
- Abstract
This review discusses major developments in chronic rhinosinusitis. The latest papers on prevalence of the disease, the burden for patients and society, the lack of awareness, the development of patient classifications and the consequences for the management of the disease. Our discussion includes major developments in the treatment of the disease with biologics but also their limitations. Recent developments also include evolution in the goals of care, where until recently we were content with control of disease but now start to aim for remission and maybe even cure. To reach that aim we need better definitions of disease, outcomes and biomarkers to predict the optimal moment of intervention in the development of the disease. Time will tell whether earlier intervention can prevent development of the disease and later sequelae.
- Published
- 2024
- Full Text
- View/download PDF
20. Nasal endoscopy score thresholds to trigger consideration of chronic rhinosinusitis treatment escalation and implications for disease control.
- Author
-
Sedaghat AR, Cotter RA, Alobid I, Alsaleh S, Anselmo-Lima WT, Bernal-Sprekelsen M, Chandra RK, Constantinidis J, Fokkens WJ, Franzese C, Gray ST, Halderman AA, Holbrook EH, Hopkins C, Hwang PH, Kuan EC, Landis BN, Lund VJ, McCoul ED, Niederberger-Leppin V, O'Brien EK, Philpott CM, Pletcher SD, Pynnonen MA, Reitsma S, Rimmer J, Toppila-Salmi S, Wang EW, Wang MB, Wise SK, Woodworth BA, Yao WC, and Phillips KM
- Abstract
Background: In the absence of direct evidence supporting how to use nasal endoscopy findings to judge chronic rhinosinusitis (CRS) disease control, experts' practice patterns could provide guidance., Methodology: Participants consisted of a diverse group of twenty-nine rhinologists. Participants were presented with every possible combination of bilateral nasal endoscopy findings represented by the modified Lund-Kennedy (MLK; range: 0-12) endoscopic scoring system and Nasal Polyp Score (NPS; range: 0-8). Reflecting the practical consequence of CRS disease control assessment, participants were asked whether they would consider CRS treatment escalation based on each scenario in the absence of any CRS symptoms, and how strongly they considered escalating therapy. The same scenarios were then presented in the context of 1 burdensome CRS symptom and participants again were asked whether they would consider treatment escalation., Results: The median threshold total MLK score for considering treatment escalation was ≥4 and 75.9% of participants' MLK thresholds were within 1 point of 4. The median threshold total NPS for considering treatment escalation was ≥3 and 62.5% of participants' NPS thresholds were within 1 point of 3. Endoscopy score thresholds decreased in the presence of 1 burdensome symptom and generally increased when requiring stronger affirmation for considering CRS treatment escalation., Conclusion: Reflecting the practice patterns of a diverse group of rhinologists, MLK score ≥4 or NPS ≥3 may serve as thresholds for considering CRS treatment escalation. Alternatively, MLK score.
- Published
- 2024
- Full Text
- View/download PDF
21. The impact of mepolizumab on sleep impairment in CRSwNP: post hoc analyses of SYNAPSE and MUSCA.
- Author
-
Mullol J, Fokkens WJ, Smith SG, Keeley T, Zhang L, Howarth P, Chan RH, and Bachert C
- Abstract
Background: The impact of mepolizumab on impaired sleep, one of the most bothersome symptoms in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), is unknown. This study aimed to determine the effect of mepolizumab and impact of comorbid upper and lower airway disease and blood eosinophil count (BEC) on sleep-/fatigue-related outcomes in CRSwNP., Methods: This was an analysis of the Phase III SYNAPSE and MUSCA (NCT03085797/NCT02281318) trials of mepolizumab in patients with severe CRSwNP and severe asthma, respectively. Endpoints included change from baseline in 22-item Sino-Nasal Outcome Test (SNOT-22) sleep and fatigue domains (SYNAPSE: Weeks 24 and 52; MUSCA: Week 24) in the overall populations and post hoc subgroups (SYNAPSE: comorbid asthma, comorbid non-steroidal anti-inflammatory drug-exacerbated respiratory disease [N-ERD] and BEC; MUSCA: comorbid CRSwNP)., Results: In SYNAPSE, 289/407 patients with severe CRSwNP had comorbid asthma, 108 had N-ERD, and 278 had BEC ≥300 cells/µL. In MUSCA, 105/551 patients with severe asthma had comorbid CRSwNP. Baseline sleep and fatigue scores were worse in patients with comorbid airway disease and higher BEC. Improvements from baseline in sleep and fatigue scores were greater with mepolizumab versus placebo at Week 52 in SYNAPSE (difference in least squares mean change: -2.7 [sleep], -3.4 [fatigue], and Week 24 in SYNAPSE (-1.6 and -2.2) and MUSCA (-0.8 and -1.2), with consistent results across comorbidity and BEC subgroups., Conclusion: Mepolizumab improves sleep and fatigue in severe CRSwNP, irrespective of comorbid airway disease and BEC, with consistent effects in severe asthma with and without comorbid CRSwNP.
- Published
- 2024
- Full Text
- View/download PDF
22. Outcome measures for chronic rhinosinusitis with nasal polyps.
- Author
-
Sedaghat AR, Campbell RG, Douglas RG, Fokkens WJ, Hamizan AW, Korban ZR, Lee VS, Macias-Valle L, Romano FR, Snidvongs K, and Alsaleh S
- Subjects
- Humans, Chronic Disease, Quality of Life, Biomarkers analysis, Biomarkers blood, Outcome Assessment, Health Care, Rhinosinusitis, Sinusitis therapy, Sinusitis complications, Sinusitis diagnosis, Nasal Polyps complications, Nasal Polyps therapy, Nasal Polyps diagnosis, Rhinitis therapy, Rhinitis diagnosis, Rhinitis complications, Patient Reported Outcome Measures
- Abstract
Background: With the recent proliferation of novel therapeutics for chronic rhinosinusitis with nasal polyps (CRSwNP), there is an immediate need for comprehensive means to assess CRSwNP disease status as well as to determine treatment efficacy. Outcome measures exist in different forms. Patient-reported outcome measures (PROMs) allow patients to provide direct input about their condition that is not possible to obtain in any other way. Common constructs that are measured using PROMs include quality of life or the burden of disease manifestations (e.g., symptom severity). Outcomes may also include the results of objective diagnostic testing/measurement of clinical signs or measured using psychophysical tests. Biomarkers represent an emerging class of outcome measures for CRSwNP and are chosen to directly reflect the active pathophysiologic processes of CRSwNP in the peripheral blood, sinus/polyp tissues, and sinonasal mucus., Methods: Narrative review of the literature, identifying and describing outcome measures that may be used in the evaluation of CRSwNP and for assessment of treatment responses., Results: In this review, we identify many different outcome measures for CRSwNP that fall under the categories of PROM, objective test, psychophysical test or biomarker. We describe the history of each - including seminal studies - and demonstrate the formal validation, psychometric performance, and limitations of each., Conclusions: PROMs, objective tests, psychophysical tests and biomarkers represent different classes of outcome measures that are complementary means of assessing CRSwNP disease status and treatment efficacy. The choice or interpretation of a CRSwNP outcome measure should be undertaken with full knowledge of its formal validation, psychometric performance, and limitations.
- Published
- 2024
- Full Text
- View/download PDF
23. Steroid responsiveness predicts olfactory function recovery in dupilumab treated CRSwNP.
- Author
-
Otten JJ, van der Lans RJL, Benoist LB, Adriaensen GFJPM, Hoven RD, Verkest V, Fokkens WJ, and Reitsma S
- Subjects
- Humans, Retrospective Studies, Male, Female, Middle Aged, Chronic Disease, Recovery of Function, Adult, Smell drug effects, Adrenal Cortex Hormones therapeutic use, Olfaction Disorders drug therapy, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Sinusitis drug therapy, Nasal Polyps drug therapy, Nasal Polyps complications, Rhinitis drug therapy
- Abstract
Background: There is no known predictor for olfactory function recovery with dupilumab treatment in chronic rhinosinusitis with nasal polyps (CRSwNP). This study assessed whether patient-reported recovery of olfactory function on oral corticosteroids (OCS) is a prognostic factor., Methods: Retrospective analysis of pre-biological OCS-responsiveness on olfactory functioning (OCS-responsive or OCS-unresponsive; OCS-r and OCR-u, respectively) as predictor for olfactory functioning after 6 months of dupilumab therapy for severe CRSwNP., Results: 212 CRSwNP patients treated with dupilumab were divided between OCS-r (reported improvement of olfactory function with OCS before dupilumab treatment, n = 152), and OCS-u (OCS-unresponsive; no such improvement, n = 60). Olfactory function was tested with Sniffin's Sticks Identification Test (12 pens; SSIT-12). At baseline, both groups had a median SSIT-12 score of 3 / 12 indicating anosmia. Hyposmia and normosmia rates were also comparable (5.9% and 3.3% in OCS-r, respectively; 5.0% and 1.7% in OCS-u, respectively). After 6 months of dupilumab treatment, OCS-r showed higher olfactory scores (median SSIT-12: 8/12; 52.6% hyposmia and 17.8% normosmia) than OCS-u (median SSIT-12: 5/12; 31.7% hyposmia and 3.3% normosmia). The positive predictive value of OCS-responsiveness on scoring <7 (normosmia/hyposmia) on the SSIT-12 after 6 months of dupilumab treatment was 70.4%. Conversely, the negative predictive value of OCS-unresponsiveness on scoring <7 (anosmia) on the SSIT-12 after 6 months of dupilumab treatment was 65.0%., Conclusion: Patients who report olfactory function improvement on OCS have a higher chance of recovery of olfactory function during the first six months of treatment with dupilumab than patients who do not.
- Published
- 2024
- Full Text
- View/download PDF
24. Revision surgery, biologics, or both?
- Author
-
Fokkens WJ
- Subjects
- Humans, Biological Products therapeutic use, Reoperation statistics & numerical data
- Published
- 2024
- Full Text
- View/download PDF
25. Eosinophils are the dominant type2 marker for the current indication of biological treatment in severe uncontrolled chronic rhinosinusitis with nasal polyps.
- Author
-
van der Lans R, Otten JJ, Adriaensen GFJPM, Benoist LBL, Cornet ME, Hoven DR, Rinia AB, Fokkens WJ, and Reitsma S
- Subjects
- Humans, Chronic Disease, Immunoglobulin E blood, Leukocyte Count, Rhinosinusitis, Nasal Polyps complications, Nasal Polyps therapy, Sinusitis complications, Sinusitis blood, Sinusitis therapy, Rhinitis complications, Rhinitis blood, Eosinophils, Biomarkers blood, Biomarkers analysis
- Abstract
The latest European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020) defines markers for type2 inflammation in the context of indicating biological therapy in severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) as either a total serum immunoglobulin E (total-IgE) <100 kU/L, a blood eosinophil count (BEC, expressed as -109 cells / L) >=0.25, or a tissue eosinophil count >=10 per high power field (HPF) (1). Recently, an EPOS/EUFOREA expert panel advised to lower the threshold for BEC from >=0.25 (EPOS2020) to >=0.15 (EUFOREA2023) to align with thresholds used for biological indication in asthma patients (2). As far as we know, there is no literature supporting the cut-off value for total-IgE.
- Published
- 2024
- Full Text
- View/download PDF
26. Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.
- Author
-
Mullol J, Lund VJ, Wagenmann M, Han JK, Sousa AN, Smith SG, Mayer B, Chan RH, and Fokkens WJ
- Subjects
- Humans, Chronic Disease, Female, Male, Adult, Middle Aged, Olfaction Disorders drug therapy, Olfaction Disorders etiology, Smell drug effects, Smell physiology, Double-Blind Method, Treatment Outcome, Sino-Nasal Outcome Test, Rhinosinusitis, Sinusitis drug therapy, Sinusitis complications, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Nasal Polyps drug therapy, Nasal Polyps complications, Rhinitis drug therapy, Rhinitis complications
- Abstract
Background: Loss of smell is one of the most bothersome and difficult-to-treat symptoms in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP)., Methodology: SYNAPSE was a 52-week Phase III study of 4-weekly mepolizumab (100 mg subcutaneously) plus standard of care in adults with severe bilateral CRSwNP. This post hoc analysis assessed changes from baseline to study end in loss of smell visual analogue scale (VAS) symptom score, in patients stratified by several baseline clinical characteristics. SinoNasal Outcomes Test (SNOT)-22 sense of smell/taste item and University of Pennsylvania Smell Identification Test (UPSIT) scores were also assessed., Results: SYNAPSE enrolled 407 patients (mepolizumab=206; placebo=201) with impaired sense of smell at baseline. Improvements from baseline to study end in loss of smell VAS score were greater with mepolizumab versus placebo (treatment difference: -0.37) and most notable in patients with fewer or more recent prior surgeries (treatment difference: 1 vs 2 vs more than 2 prior surgeries,-1.29 vs -0.23 vs -0.07; =3 years since last surgery, -.89 vs 0.22). Approximately 25% of patients had baseline UPSIT scoresavailable; among those scoring =19 by study end. The SNOT-22 sense of smell/taste item score improved with mepolizumab versus placebo., Conclusions: Mepolizumab treatment improved patients' perceived sense of smell, as measured by loss of smell VAS score and SNOT-22 sense of smell/taste item score in patients with severe refractory CRSwNP.
- Published
- 2024
- Full Text
- View/download PDF
27. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.
- Author
-
Hellings PW, Alobid I, Anselmo-Lima WT, Bernal-Sprekelsen M, Bjermer L, Caulley L, Chaker A, Constantinidis J, Conti DM, De Corso E, Desrosiers M, Diamant Z, Gevaert P, Han JK, Heffler E, Hopkins C, Landis BN, Lourenco O, Lund V, Luong AU, Mullol J, Peters A, Philpott C, Reitsma S, Ryan D, Scadding G, Senior B, Tomazic PV, Toskala E, Van Zele T, Viskens AS, Wagenmann M, and Fokkens WJ
- Subjects
- Humans, Chronic Disease, Disease Management, Nasal Polyps therapy, Nasal Polyps diagnosis, Rhinosinusitis diagnosis, Rhinosinusitis therapy
- Abstract
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
28. Hypereosinophilia during dupilumab treatment in patients with chronic rhinosinusitis with nasal polyps.
- Author
-
Kemp P, van der Lans RJL, Otten JJ, Adriaensen GFJPM, Benoist LBL, Cornet ME, Hoven DR, Rinia B, Verkest V, Fokkens WJ, and Reitsma S
- Subjects
- Adult, Humans, Cross-Sectional Studies, Prospective Studies, Chronic Disease, Nasal Polyps complications, Nasal Polyps drug therapy, Nasal Polyps epidemiology, Rhinosinusitis, Rhinitis complications, Rhinitis drug therapy, Sinusitis complications, Sinusitis drug therapy, Sinusitis epidemiology, Eosinophilia, Antibodies, Monoclonal, Humanized
- Abstract
Background: Increased blood eosinophil count (BEC) is common in patients under dupilumab treatment for chronic rhinosinusitis with nasal polyps (CRSwNP). This study investigated the prevalence and consequences of hypereosinophilia and to help define patients at risk., Methods: Real-life, prospective observational cohort study of patients treated with dupilumab for severe CRSwNP. Eligible patients were adult and biological-naive (N=334). All BEC values at baseline and during treatment were reported. Patients with a follow-up of >= 1 year were included to define patients at risk for hypereosinophilia by comparing baseline BEC values (N=218). Furthermore, clinical characteristics and therapeutic consequences for patients with BEC >= 3.0 were noted., Results: Hypereosinophilia developed in a minority of patients, with a peak at week 12 (16.2% with BEC >= 1.5, and 1.7% >= 3.0) in cross-sectional analysis. BEC >= 1.5 developed in 28.9% and BEC >=3.0 in 4.6% of cases with a minimal 1-year follow-up. Baseline BEC was significantly higher for patients developing BEC >= 1.5 and BEC >=3.0, with an optimal cut-off point of 0.96 to predict developing BEC >= 3.0., Conclusions: Blood eosinophil count (BEC) >= 1.5 is transient and usually abates with no therapeutic interventions and BEC >= 3.0 is rare. Hypereosinophilic syndrome did not occur and switching to a different biological was rarely employed. A baseline BEC of >=1.0 can be a reason for extra caution.
- Published
- 2024
- Full Text
- View/download PDF
29. Global CRSwNP Awareness Day and the European Society meeting in Sofia.
- Author
-
Fokkens WJ
- Published
- 2023
- Full Text
- View/download PDF
30. Evaluating treatment response to mepolizumab in patients with severe CRSwNP.
- Author
-
Hopkins C, Han JK, Lund VJ, Bachert C, Fokkens WJ, Diamant Z, Mullol J, Sousa AR, Smith SG, Yang S, Mayer B, Yancey SW, Chan RH, and Lee SE
- Subjects
- Humans, Quality of Life, Antibodies, Monoclonal, Humanized therapeutic use, Chronic Disease, Adrenal Cortex Hormones therapeutic use, Nasal Obstruction drug therapy, Nasal Polyps complications, Nasal Polyps drug therapy, Rhinitis complications, Rhinitis drug therapy
- Abstract
Background: The SYNAPSE study (NCT03085797) demonstrated that mepolizumab decreased nasal polyp (NP) size and nasal obstruction in patients with chronic rhinosinusitis with NP (CRSwNP)., Methods: SYNAPSE, a randomized, double-blind study, included patients with recurrent, refractory, severe CRSwNP, eligible for repeated surgery despite receiving standard of care (SoC). Patients received 4-weekly mepolizumab 100 mg or placebo subcutaneously plus SoC for 52 weeks. This post hoc analysis further characterized treatment responses and association with patient characteristics. The proportion of patients meeting any and each of five response criteria indicating improvement in disease-specific quality of life, NP size, nasal obstruction, loss of smell, and overall symptoms at Weeks 24 and 52, were assessed in subgroups: 1) no surgery; 2) neither surgery nor systemic corticosteroids (SCS)., Results: Of 407 patients in the intention-to-treat population, 381 and 343 patients had no sinus surgery by Weeks 24 and 52, respectively. More mepolizumab- versus placebo-treated patients without surgery by Weeks 24 and 52 met each response criteria. Of the mepolizumab-treated patients without surgery by Week 24, 109 (55%) responded across >=3 criteria, increasing to 126 (67%) by Week 52. Similar response trends were seen for patients with neither surgery nor SCS by Weeks 24 and 52. At either timepoint, there were no major differences in baseline characteristics between mepolizumab-treated full- (5/5 categories) and non-responders (0/5 categories)., Conclusions: Most patients who completed SYNAPSE required neither surgery nor SCS use and in addition achieved a progressive and sustained clinical response to mepolizumab underscoring the therapeutic benefits of mepolizumab in severe CRSwNP.
- Published
- 2023
- Full Text
- View/download PDF
31. Changing habits.
- Author
-
Fokkens WJ
- Published
- 2023
- Full Text
- View/download PDF
32. Measuring control of disease in Chronic Rhinosinusitis; assessing the correlation between SinoNasal Outcome Test-22 and Visual Analogue Scale item scores.
- Author
-
Dietz de Loos DAE, Cornet ME, Hopkins C, Fokkens WJ, and Reitsma S
- Subjects
- Humans, Sino-Nasal Outcome Test, Visual Analog Scale, Chronic Disease, Quality of Life, Rhinitis diagnosis, Rhinitis therapy, Sinusitis diagnosis, Sinusitis therapy
- Abstract
Background: In chronic rhinosinusitis (CRS), aim of treatment is control of disease. EPOS2020 suggests the use of visual analogue scale (VAS) measurements on several symptoms. We aim to determine if individual VAS items can be replaced by widely used SinoNasal Outcome Test-22 (SNOT-22) items when determining control of disease, to avoid using double measurements and to stimulate its use in clinical practice., Methods: Analyses were made on correlations between individual SNOT-22 scores and symptom-specific questions from consecutive patients with CRS visiting our tertiary referral rhinologic clinic for the first time., Results: 157 CRS patients were included. Correlations of individual items were strong (r greater than 0.8). Best parity in sensitivity, specificity, positive predicting value, negative predicting value, odds ratio and Receiver Operating Characteristic curves were found in individual item score of VAS greater than 5 and SNOT item-score. This cut off is valid for measuring control of disease, combining several nasal, facial pain and sleep symptoms (controlled, partially controlled and uncontrolled)., Conclusion: There is strong correlation between individual items measured as SNOT or VAS. For the definition of CRS disease control, as proposed in EPOS2020, the use of symptoms specific SNOT 23 is predictive of VAS greater than 5.
- Published
- 2023
- Full Text
- View/download PDF
33. Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP.
- Author
-
Bachert C, Hellings PW, Lund VJ, Fokkens WJ, Hopkins C, Mayer B, Chan RH, Smith SG, Sousa AR, Alfonso-Cristancho R, Yang S, and On Behalf Of The Synapse Study Group OBOTSSG
- Subjects
- Humans, Quality of Life, Antibodies, Monoclonal, Humanized therapeutic use
- Abstract
Mepolizumab improves quality of life and reduces activity impairments in patients with CRSwNP.
- Published
- 2022
- Full Text
- View/download PDF
34. European Rhinologic Society meeting 2021. Safe in person meeting in times of COVID-19.
- Author
-
Fokkens WJ, Meco C, Constantinidis J, Zhang N, and Hopkins C
- Subjects
- Humans, COVID-19, Otolaryngology
- Published
- 2022
- Full Text
- View/download PDF
35. Unmet needs in biological treatment of CRS.
- Author
-
Fokkens WJ
- Published
- 2022
- Full Text
- View/download PDF
36. Endoscopic grading systems for nasal polyps: are we comparing apples to oranges?
- Author
-
Djupesland PG, Reitsma S, Hopkins C, Sedaghat AR, Peters A, and Fokkens WJ
- Subjects
- Humans, Administration, Intranasal, Endoscopy, Chronic Disease, Nasal Polyps drug therapy, Rhinitis drug therapy, Sinusitis drug therapy
- Abstract
Endoscopic grading of nasal polyps (NP) is typically a coprimary endpoint in clinical trials evaluating treatments for chronic rhinosinusitis with nasal polyps (CRSwNP). However, a consensus on the most effective way to grade nasal polyps has not been reached. Different scales have been used, hampering the interpretation of data across trials. This review compares the characteristics of NP grading systems used in registration trials for approved NP treatments. These fundamental differences in grading systems make quantitative comparison of outcomes between trials inaccurate and potentially misleading. In lieu of a universal grading system, reporting the baseline distribution of polyp grades (unilateral and/or summed/total grades), as well as changes from baseline over time by baseline grade may help improve interpretability of outcomes and reduce inaccuracy when attempting cross-trial comparisons and making therapeutic decisions.
- Published
- 2022
- Full Text
- View/download PDF
37. Rhinology in review: from COVID-19 to biologicals.
- Author
-
Fokkens WJ, Landis BN, Hopkins C, Reitsma S, and Sedaghat AR
- Subjects
- Chronic Disease, Humans, SARS-CoV-2, Smell, Biological Products therapeutic use, COVID-19, Nasal Polyps, Olfaction Disorders, Rhinitis drug therapy, Sinusitis
- Abstract
We look back at the end of what soon will be seen as an historic year, from COVID-19 to real-world introduction of biologicals influencing the life of our patients. This review describes the important findings in Rhinology over the past year. A large body of evidence now demonstrates loss of sense of smell to be one of the most common symptoms of COVID-19 infection; a meta-analysis of 3563 patients found the mean prevalence of self-reported loss to be 47%. A number of studies have now shown long-term reduced loss of smell and parosmia. Given the high numbers of people affected by COVID-19, even with the best reported recovery rates, a significant number worldwide will be left with severe olfactory dysfunction. The most prevalent causes for olfactory dysfunction, besides COVID-19 and upper respiratory tract infections in general, are trauma and CRSwNP. For these CRSwNP patients a bright future seems to be starting with the development of treatment with biologics. This year the Nobel prize in Medicine 2021 was awarded jointly to David Julius and Ardem Patapoutian for their discoveries of receptors for temperature and touch which has greatly enhanced our understanding of nasal hyperreactivity and understanding of intranasal trigeminal function. Finally, a new definition of chronic rhinitis has been proposed in the last year and we have seen many papers emphasizing the importance of endotyping patients in chronic rhinitis and rhinosinusitis in order to optimise treatment effect.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.